肉毒毒素治疗慢性鼻炎的系统评价与Meta分析
该系统评价与Meta分析纳入9项RCT共340例慢性鼻炎患者,评估A型肉毒毒素(BTX-A)的疗效与安全性。与安慰剂相比,BTX-A在≤12周改善总鼻部症状评分(TNSS),且疗效可持续至24周;与部分活性对照药相比疗效相当或更优,不良事件风险较低。
要点
- BTX-A在≤12周可改善慢性鼻炎患者TNSS,疗效可持续至24周。
- BTX-A对鼻塞及单个鼻部症状的改善未显示优于安慰剂。
- BTX-A安全耐受,可考虑用于对标准治疗无效的患者。
核心结论
- BTX-A可改善慢性鼻炎患者的TNSS和生活质量,疗效可持续至治疗后24周。
- BTX-A安全、耐受良好,可考虑用于对当前标准治疗无效的患者。
研究设计与样本
- 系统检索MEDLINE、Scopus和EMBASE数据库,纳入比较BTX-A与安慰剂或活性治疗的随机对照试验(RCT)。
- 共纳入9项RCT、340例过敏性鼻炎和/或非过敏性鼻炎患者。
主要发现
- 与安慰剂相比,≤12周BTX-A注射改善TNSS(SMD -2.22,95%CI -3.27至-1.17,p<0.01,4项RCT)。
- 与安慰剂相比,>12周BTX-A对TNSS的益处持续至24周(MD -9.69,95%CI -11.29至-8.09,p<0.01,1项RCT)。
- 与安慰剂相比,BTX-A对鼻塞和单个鼻部症状的改善未显示获益。
- 与活性对照药(曲安奈德注射、异丙托溴铵、西替利嗪)相比,≤12周TNSS组间无差异。
- BTX-A与西替利嗪在生活质量上无差异(1项RCT);>12周TNSS和单个鼻部症状方面BTX-A优于曲安奈德注射(1项RCT);不良事件风险比方面BTX-A优于西替利嗪(1项RCT)。
临床怎么用
- 对于当前标准治疗无效的慢性鼻炎患者,可考虑BTX-A治疗。
- BTX-A对总鼻部症状的改善可持续至24周,但对鼻塞的改善证据不足。
局限性
- 部分结局仅基于单项RCT,证据有限。
- 未报告对鼻塞和单个鼻部症状的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Botulinum toxin type A (BTX-A) is a potential treatment for chronic rhinitis. This study aimed to assess the effectiveness and safety of BTX-A in treating patients with chronic rhinitis. METHODS: Systematic searches of MEDLINE, Scopus, and EMBASE databases were performed. Randomized controlled trials (RCTs) that assessed the efficacy of BTX-A in allergic rhinitis and/or nonallergic rhinitis patients, compared with either placebo or active treatment, were included. The outcomes were total nasal symptom (TNSS), disease-specific quality of life (QOL), and adverse events. RESULTS: Nine RCTs (340 patients) met the eligibility criteria. Compared with placebo, the ≤ 12-week effects favored BTX-A injection on TNSS (standardized mean difference [SMD] -2.22, 95% confidence interval [CI] -3.27 to -1.17, p < 0.01, four RCTs). Beneficial effects > 12 weeks over placebo (MD -9.69, 95% CI -11.29 to -8.09, p < 0.01, one RCT) were demonstrated up to 24 weeks. However, the benefits were not shown on nasal congestion and individual nasal symptoms. Compared with active comparators (triamcinolone injection, ipratropium bromide, and cetirizine), there was no difference in the < 12-week effect between groups on TNSS. There was no difference between BTX-A and cetirizine on QOL (one RCT). The > 12-week effects on TNSS and individual nasal symptoms favored BTX-A over triamcinolone injection (one RCT). The risk ratio of adverse events favored BTX-A over cetirizine (one RCT). CONCLUSIONS: BTX-A improved TNSS and QOL in patients with chronic rhinitis. These effects were demonstrated up to 24 weeks post treatment. BTX-A was safe, well tolerated, and may be considered in patients who are refractory to current standard-of-care therapies.
引用
- Rinzin K, Hoang MP, Seresirikachorn K, et al. Botulinum toxin for chronic rhinitis: A systematic review and meta-analysis. Int Forum Allergy Rhinol. 2021. PMID: 33956405. doi:10.1002/alr.22813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。